文献速递免疫规划卫生政策与健康促进

135个中低收入国家轮状病毒疫苗接种的死亡减少获益与肠套叠风险:当前及替代接种方案的模型分析

Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules.
PubMed 文献 · Lancet Glob Health · 2019-01-01

该模型分析纳入135个中低收入国家,评估2015年出生队列至5岁期间轮状病毒疫苗接种的死亡减少获益与肠套叠风险。三剂次DTP同期接种方案可预防约74000例胃肠炎死亡(38%减少),导致201例超额肠套叠死亡(1.4%增加),获益-风险比为369:1。新生儿期接种方案可能预防更多死亡并导致更少超额肠套叠死亡,但需更有效的疫苗。

要点

  • 三剂次DTP同期接种方案获益-风险比为369:1(95%UI 160:1-895:1)
  • 首剂与BCG、第二剂与DTP1同期接种的方案超额肠套叠死亡最少、获益-风险比最优
  • 新生儿期方案可能优于WHO当前推荐方案,但需更有效疫苗

核心结论

  • 轮状病毒疫苗在中低收入国家具有有利的获益-风险特征,新生儿期方案可能预防更多胃肠炎死亡并导致更少超额肠套叠死亡,但需更有效疫苗以实现更大死亡减少获益。

研究设计与样本

  • 采用Excel静态队列模型,年龄结构精细拆分,纳入2015年出生至5.0岁的所有婴儿。
  • 纳入135个中低收入国家(2018财年人均国民总收入低于12236美元)。
  • 评估WHO当前推荐的两种方案及16种替代方案,共18种方案。
  • 假设接种1至3剂,首剂与BCG或DTP1同期接种,第二或第三剂与DTP1、DTP2、DTP3或Meas1同期接种。

主要发现

  • 三剂次DTP同期接种方案(无年龄限制)较不接种可预防约74000例(95%UI 59000-100000)轮状病毒胃肠炎死亡(38%减少),并导致201例(77-550)超额肠套叠死亡(1.4%增加),获益-风险比369:1(160:1-895:1)。
  • 当假设肠套叠相对风险随国家5岁以下死亡率下降而降低时,获益-风险比最有利(2386:1);当对肠套叠治疗可及性持悲观假设时,获益-风险比最差(168:1)。
  • 首剂与BCG、第二剂与DTP1同期接种的方案超额肠套叠死亡最少,获益-风险比最有利。

关键数值与推荐

  • 三剂次DTP同期接种方案(无年龄限制)较不接种:预防约74000例(95%UI 59000-100000)轮状病毒胃肠炎死亡(38%减少),导致201例(77-550)超额肠套叠死亡(1.4%增加),获益-风险比369:1(160:1-895:1)。
  • 肠套叠相对风险随国家5岁以下死亡率下降而降低的假设下,获益-风险比为2386:1。
  • 对肠套叠治疗可及性持悲观假设下,获益-风险比为168:1。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infant rotavirus vaccines have led to substantial reductions in hospital admissions and deaths due to gastroenteritis, but some studies have reported an elevated risk of intussusception, a rare bowel disorder. This analysis aimed to provide evidence on the potential mortality reduction benefits and intussusception risks of current rotavirus vaccination schedules, and to explore whether alternative schedules could have advantages. METHODS: All 135 low-income and middle-income countries, defined by gross national income per capita of less than US$12 236 in the 2018 fiscal year, were included in the model. Mortality reduction benefits and intussusception risks of rotavirus vaccination were modelled by use of an Excel-based static cohort model with a finely disaggregated age structure. Numbers of rotavirus gastroenteritis deaths and intussusception deaths in each week of age were calculated for all infants born in the year 2015 between birth and age 5·0 years, with and without restrictions on age at administration. Benefit-risk ratios (rotavirus gastroenteritis deaths prevented per excess intussusception death) and other indicators were calculated for two vaccination schedules currently recommended by WHO and 16 alternative schedules. Of these schedules, it was assumed that between one and three doses would be given; the first dose of the rotavirus vaccine would be co-administered with either BCG or diphtheria-tetanus-pertussis (DTP)1; and the second or third dose would be co-administered with either DTP1, DTP2, DTP3, or measles (Meas)1. FINDINGS: A three-dose schedule co-administered with DTP (without age restrictions) could prevent about 74 000 (95% uncertainty interval 59 000-100 000) rotavirus gastroenteritis deaths (38% reduction) and could lead to 201 (77-550) excess intussusception deaths (1·4% increase) compared with no vaccination, resulting in a benefit-risk ratio of 369:1 (160:1-895:1). The benefit-risk ratio was most favourable when the relative risk of intussusception was assumed to decline with the national under-5 mortality rate (2386:1) and least favourable with pessimistic assumptions about access to hospital for intussusception treatment (168:1). Schedules that involve giving the first dose with BCG and the second with DTP1 had the fewest excess intussusception deaths and most favourable benefit-risk ratios. INTERPRETATION: Rotavirus vaccines have a favourable benefit-risk profile in LMICs. Neonatal schedules have the potential to prevent more rotavirus gastroenteritis deaths and cause fewer excess intussusception deaths than the schedules currently recommended by WHO, but more efficacious rotavirus vaccines would be needed to achieve more substantial mortality reduction benefits. FUNDING: Bill & Melinda Gates Foundation.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. Lancet Glob Health. 2019. PMID: 31607466. doi:10.1016/S2214-109X(19)30412-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。